Analyst firms · Barclays · ILMN
Barclays ILMN price target and rating history
Illumina Inc. (ILMN) · Health Care
Barclays rates Illumina Inc. (ILMN) Underweight with a $100 price target, as of its latest action on Feb 10, 2025. It has published 8 rating actions on ILMN since July 2021, including 3 upgrades and 2 downgrades. Across 5 firms with a ILMN price target in the last 12 months, the median target is $185.
- Current rating
- Underweight
- Price target
- $100
- Median target, all firms
- $185
- Actions on ILMN
- 8
Barclays price target on ILMN
Every Barclays rating on ILMN
- Feb 10, 2025
- Aug 14, 2024
- Jul 13, 2022
- Jan 12, 2022
- Jan 11, 2022
- Jan 10, 2022
- Aug 6, 2021
- Jul 13, 2021
How other firms rate ILMN
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Stephens | Equal-Weight | $275 | Oct 23, 2026 |
| UBS | Buy | $260 | Sep 9, 2026 |
| Bernstein | Mkt Perform | $185 | Jun 26, 2026 |
| RBC Capital Markets | Outperform | $170 | May 15, 2026 |
| Daiwa | Outperform | $155 | May 14, 2026 |
Questions about Barclays and ILMN
- What is Barclays's price target for ILMN?
- Barclays's latest stated price target for Illumina Inc. (ILMN) is $100, from its action on Feb 10, 2025.
- What is Barclays's rating on ILMN?
- Barclays rates ILMN Underweight, a bearish rating, as of Feb 10, 2025.
- When did Barclays last change its view on ILMN?
- On Feb 10, 2025, Barclays downgrades to Underweight from Equal Weight, price target $130 to $100.
- How does Barclays's ILMN target compare with other analysts?
- Across 5 firms with a ILMN price target in the last 12 months, the median target is $185.
More ILMN rating histories
All Barclays ratingsILMN news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.